Abstract
Twenty-six patients diagnosed as chronic schizophrenics were given injections of zuclopenthixol decanoate (cis(Z)-clopenthixol decanoate) 200 mg every 3 weeks for at least 6 months. Before treatment and on each day of injection the patients' mental state was assessed by Brief Psychiatric Rating Scale (BPRS), 18 items. A registration of side effects and basal laboratory data was also performed. Blood samples were drawn on each day of injection before injection and 3–7 days after injection (time of maximum concentration). Neuroleptic activity, which was considered equivalent to the concentration of zuclopenthixol, was determined in serum by radio-receptor assay (RRA). Based on amelioration scores ≥50% on the BPRS, 15 patients were characterized as responders and 11 as non-responders. The responder group showed a statistically significant reduction in BPRS score, whereas this was not the case for the non-responders. Apart from a few patients, the serum concentrations showed a low intra-individual variation, but a relatively high inter-individual variation. The responder group had a significantly higher mean preinjection concentration than the non-responder group, whereas no significant difference was found in day 3–7 concentrations. The fluctuation of the serum concentration expressed as the ratio between maximum (days 3–7) and minimum (pre-inj.) was found to be significantly lower for responders than for non-responders. Thus although the present study did not demonstrate a clear relationship between serum level and clinical effect, it indicates that the best antipsychotic effect is obtained with a serum concentration which fluctuates only slightly (the ratio max/min concentration not exceeding 2.1).
Similar content being viewed by others
References
Aaes-Jørgensen T, Kirk, L, Petersen E, Danneskiold-Samsøe P, Jørgensen A (1983) Serum concentrations of the isomers of clopenthixol and a metabolite in patients givencis(Z)-clopenthixol decanoate in Viscoleo. Psychopharmacology 81:62–72
Ahlfors UG, Dencker SJ, Gravem A, Remvig J (1980) Copenthixol decanoate and perphenazine enanthate in schizophrenic patients. Acta Psychiatr Scand 61 suppl 279:77–91
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Third Ed. (DSM III) Washington DC: American Psychiatric Association 1980
Cohen BM, Herschel M, Aoba A (1979) Neuroleptic, antimuscarinic and antiadrenergic activity of chlorpromazine, thioridazine and their metabolites. Psychiatr Res 1:199–208
Cohen BM, Lipiński JP, Harris PQ, Pope HG jr, Friedman M (1980) Clinical use of radioreceptor assay for neuroleptics. Psychiatr Res 1:173–178
Creese I, Synder SH (1977) A simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 270:180–182
Curry SH, Marshall JHL (1968) Plasma levels of chlorpromazine and some of its relatively non-polar metabolites in psychiatric patients. Life Sci 7:9–17
Dom R, De Mesmaecker L, Van Den Broucke M, Van Hest T, Baro F (1978) Maintenance treatment of chronic schizophrenic patients. Acta Psychiatr Scand 57:299–304
Fekete J, Del Castilho P, Kraak JC (1981) Reversed phase liquid chromatography for extraction of pharmaceuticals from human plasma. J Chromatogr 203:319–327
Fredricson Overø K (1980) A specific fluorometric method for assay of drug levels in serum of patients treated with clopenthixol decanoate injections. Acta Psychiatr Scand 61 suppl 270: 82–103
Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Revised 1976/DHEW Publications No (ADM) 76-338
Hansen LB, Larsen N-E, Vestergaard P (1981) Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology 74:306–309
Jørgensen A, Fredricson Overø K (1980) Clopenthixol and flupentixol depot preparations in outpatients schizophrenics. III. Serum levels. Acta Psychiatr Scand 61 suppl 279:41–54
Knudsen P (1985) Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand 72 suppl 322:51–75
Peroutka SJ, Snyder SH (1980) Relationship of neuroleptic drug effects of brain dopamine, serotonin, alfa-adrenergic, and histamine receptors to clinical potency. Am J Psychiatry 137:1518–1522
Ragland J, Kinross-Wright VJ (1964) Spectrofluorometric measurement of phenothiazines. Anal Chem 36:1356–1359
Rivera-Calimlim L, Nasrallah H, Strauss J, Lasagna L (1976) Clinical response and plasma levels: Effects of dose, dosage schedules and drug interactions on plasma chlorpromazine levels. Am J Psychiatry 133:646–652
Simpson GM, Angus JWS (1970) A rating scale for extraphyramidal side effects. Acta Psychiatr Scand suppl 212:11–19
Viala A, Nhean Hou, Ba B, Durand A, Dufour H, D'Agostino N, Berda C, Jørgensen A (1984) Blood and plasma kinetics ofcis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters. Psychopharmacology 83:147–150
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Szukalski, B., Lipska, B., Welbel, L. et al. Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate. Psychopharmacology 89, 428–431 (1986). https://doi.org/10.1007/BF02412115
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF02412115